ClinicalTrials.gg

Program

AZD4916

A development code.

Its studies are led by AstraZeneca.

Furthest: phase 1, since Apr 23, 20251 company-led study, 1 open or runningNext primary completion: Dec 20, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Apr 23, 2025Apr 23, 2025Dec 20, 2027phase 1 · NCT06951880
  • Named in AstraZeneca’s own pipeline as AZD4916, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT06951880 · 160 planned · United States, United Kingdom

Ahead

  1. Dec 20, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT06951880

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06951880Healthy Participants · United States, United Kingdom1RecruitingDec 20, 2027160

How it is read

Names in the registry

  • “AZD4916”, 1 entry

Codes read as this program: AZD4916.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.